Global inequities in childhood leukemia survival have narrowed in recent years but still persist, according to data from CONCORD-2.
Treatment with ponatinib yielded better overall survival compared with allogeneic stem cell transplantation in patients with chronic phase chronic myeloid leukemia with a T315I mutation.
Combined treatment with lenalidomide, bortezomib, and dexamethasone plus transplantation significantly delayed progression in patients with multiple myeloma.
Low pretreatment disease burden improved durability of CAR T-cell therapy in patients with relapsed B-cell acute lymphoblastic leukemia.
The JAK2 and FLT3 inhibitor pacritinib induced significant and sustained spleen volume reduction and symptom reduction in patients with myelofibrosis.
Patients with relapsed or refractory multiple myeloma experienced significant indirect social costs from their disease, in addition to the direct costs.
Treatment of CML with tyrosine kinase inhibitors including imatinib, nilotinib, and dasatinib can be associated with subclinical pulmonary hypertension.
Dose-attenuated bortezomib, cyclophosphamide, and dexamethasone (VCD-lite) is a viable treatment option for vulnerable or frail adults with newly diagnosed multiple myeloma.
Patients who have survived Hodgkin lymphoma were at more than double the risk for diagnosis with a second cancer, according to the results of a recent study.
During maintenance therapy for childhood ALL, there was a general increase in DNA-incorporated thioguanine nucleotides (DNA-TGN), and this increase was associated with a lower frequency of disease relapse.